EMBC logo

Embecta Corp. Stock Price

NasdaqGS:EMBC Community·US$837.5m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 12 Fair Values set on narratives written by author

EMBC Share Price Performance

US$14.19
0.96 (7.26%)
43.2% undervalued intrinsic discount
US$25.00
Fair Value
US$14.19
0.96 (7.26%)
43.2% undervalued intrinsic discount
US$25.00
Fair Value
Price US$14.19
AnalystHighTarget US$25.00
AnalystConsensusTarget US$16.67
AnalystLowTarget US$11.83

EMBC Community Narratives

AnalystHighTarget·
Fair Value US$25 43.2% undervalued intrinsic discount

Aging And Digital Trends Will Advance Insulin Delivery Solutions

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$16.67 14.9% undervalued intrinsic discount

GLP-1 Partnerships Will Expand Global Healthcare Reach

1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AnalystLowTarget·
Fair Value US$11 29.0% overvalued intrinsic discount

Global Healthcare Margins Will Erode Under Tightening Reimbursement Pressures

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent EMBC News & Updates

Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price

Embecta: Strategic Reprioritization Holds Promise And Valuations Are Favorable

Aug 28

Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely

Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely

Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)

Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)

Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

Embecta Corp. Key Details

US$1.1b

Revenue

US$403.7m

Cost of Revenue

US$698.8m

Gross Profit

US$615.2m

Other Expenses

US$83.6m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
1.43
Gross Margin
63.38%
Net Profit Margin
7.58%
Debt/Equity Ratio
-219.3%

Embecta Corp. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with moderate growth potential.

3 Risks
4 Rewards

About EMBC

Founded
1924
Employees
2100
CEO
Devdatt Kurdikar
WebsiteView website
www.embecta.com

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 1.1%
  • 3 Months: 8.9%
  • 1 Year: 18.9%
  • Year to Date: 15.1%
Over the last 7 days, the market has risen 1.1%, driven by gains of 1.9% in the Information Technology sector. As for the past 12 months, the market is up 19%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›